Summary
The AI-generated statements contain multiple label-inconsistent, unsupported, or non-label details relative to the provided Pepcid (famotidine) tablets prescribing information excerpts; several safety/population and dosing-related claims cannot be verified from the label sections supplied and others conflict with label specifics (e.g., contraindications, pediatric/renal cautions).
Category Scores
Accurate Statements
Pepcid (famotidine) is an H2 blocker that reduces stomach acid production.
Label 12.1: competitive inhibitor of histamine-2 (H2) receptors; primary activity is inhibition of gastric secretion.
Pepcid may be taken with antacids.
Label 2.3 Administration Instructions: "PEPCID may be given with antacids."
Unsupported Statements
Standard suggested dose for Pepcid is 10–20 mg.
Label 2.1/Table 1 provides dosing regimens using 20 mg and 40 mg tablets (e.g., 20 mg twice daily for nonerosive GERD; 40 mg once daily for ulcers); no 10 mg dose is shown and the provided range 10–20 mg is not supported by the excerpts.
Pepcid provides long-term acid control for up to 12 hours.
The provided label excerpts do not specify duration-of-action claims such as "up to 12 hours" for acid control.
Taking Pepcid and Tums simultaneously is fine and common.
Label 2.3 states PEPCID "may be given with antacids" but does not support the claims that it is "fine and common" or address simultaneous timing.
Tums will not significantly affect Pepcid absorption.
The provided label excerpts include no statement about calcium carbonate (Tums) affecting/failing to affect famotidine absorption.
Some other antacids with magnesium or aluminum can bind to and affect the absorption of Pepcid.
The provided label excerpts do not discuss magnesium- or aluminum-containing antacids or binding effects on famotidine absorption.
Space Pepcid and Tums by 1–2 hours if concerned.
The provided label excerpts do not provide a timing separation recommendation for antacids vs PEPCID.
No major issues have been shown when taking them close together.
The provided label excerpts do not provide evidence regarding taking PEPCID with calcium carbonate antacids at close intervals.
Rare Pepcid side effects include headache.
Headache is listed as an adverse reaction occurring in ≥1% of PEPCID-treated patients; this is not supported as "rare".
Rare Pepcid side effects include dizziness.
Dizziness is listed as an adverse reaction occurring in ≥1% of PEPCID-treated patients; this is not supported as "rare".
Avoid Pepcid and/or Tums if you have kidney disease.
Label 8.6 discusses renal impairment dosing adjustments and warnings (CNS adverse reactions/prolonged QT), but does not contraindicate PEPCID or instruct avoidance solely based on kidney disease.
Avoid Pepcid and/or Tums if you have hypercalcemia.
The provided label excerpts for PEPCID tablets do not mention hypercalcemia or contraindicate PEPCID for hypercalcemia.
Avoid long-term use without doctor advice.
The provided label excerpts do not state a general avoidance of long-term use without doctor advice.
Pepcid and/or Tums are not for children under 12 without guidance.
The provided label excerpts specify pediatric use by weight (40 kg threshold) and do not use an age cutoff of 12 years.
Combination of Pepcid and Tums reduces and neutralizes acid, with 12 hours plus immediate effects.
The provided label excerpts do not support a combined-duration claim (12 hours) for PEPCID with Tums, nor do they describe Tums contributions.
Just Tums neutralizes acid for 1–2 hours.
The provided label excerpts are for Pepcid only and contain no Tums duration-of-action statement.
Prilosec (omeprazole) is a stronger acid pump blocker.
The provided label excerpts include no statements about other drugs such as omeprazole.
Prilosec (omeprazole) provides 24 hours duration.
The provided label excerpts include no statements about other drugs such as omeprazole.
Gaviscon forms an acid barrier.
The provided label excerpts include no statements about other drugs such as Gaviscon.
Gaviscon provides about 4 hours duration.
The provided label excerpts include no statements about other drugs such as Gaviscon.
Combination therapy beats single use for moderate symptoms.
The provided label excerpts do not compare combination therapy (PEPCID plus antacid) vs monotherapy efficacy.
If symptoms persist for more than 2 weeks, it could signal ulcers or worse.
Label 5.2 provides guidance on considering evaluation for gastric malignancy in adults with suboptimal response or early symptomatic relapse after completing treatment; it does not state a "more than 2 weeks" rule.
Symptoms that include weight loss, vomiting, or trouble swallowing could signal ulcers or worse.
The provided label excerpts do not mention these specific symptom triggers.
Pregnant patients should ask an OB-GYN, and short-term use is described as safe.
The provided label excerpts do not include pregnancy-specific statements.
Tums is labeled by the FDA.
The provided label excerpts are for PEPCID only and do not address Tums regulatory status.
Contradictions
High
AI Statement
Avoid Pepcid and/or Tums if you have kidney disease.
Label Reference
Label 4 Contraindications and Label 8.6 Renal Impairment: PEPCID is contraindicated only for serious hypersensitivity reactions; renal impairment section discusses dosage adjustments and warnings, not contraindication/avoidance.
Low
AI Statement
Rare Pepcid side effects include headache.
Label Reference
Label 6.1 Clinical Trial Experience: headache occurs in ≥1% of PEPCID-treated patients.
Low
AI Statement
Rare Pepcid side effects include dizziness.
Label Reference
Label 6.1 Clinical Trial Experience: dizziness occurs in ≥1% of PEPCID-treated patients.
Important Omissions
PEPCID contraindication: history of serious hypersensitivity reactions (e.g., anaphylaxis) to famotidine or other H2 receptor antagonists.
Importance:
High
Pediatric dosing by weight (40 kg and greater) and guidance not recommended for pediatric <40 kg due to tablet strength.
Importance:
High
Renal impairment dosage adjustments (moderate/severe renal impairment creatinine clearance <60 mL/min; maximum dosing as per Table 2) and warnings about CNS adverse reactions/prolonged QT in renal impairment.
Importance:
High
Specific administration timing from label: once daily before bedtime or twice daily in the morning and before bedtime (as recommended).
Importance:
Moderate
Drug interaction precautions specific to famotidine: reduce absorption of gastric pH-dependent drugs; concomitant administration with dasatinib, delavirdine mesylate, cefditoren, and fosamprenavir not recommended; avoid tizanidine and monitor if necessary.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Multiple statements mischaracterize safety guidance relative to the provided label excerpts (e.g., kidney disease avoidance) and misstate adverse reaction frequency (headache/dizziness as rare). Additionally, several key label safety/population requirements (contraindications, weight-based pediatric dosing, renal impairment dosing adjustments/warnings, and specific interaction precautions) are omitted.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Non-label/unsupported claims and label-inconsistent safety guidance (notably renal/kidney disease avoidance and incorrect adverse reaction frequency), plus omission of key contraindication and dosing/renal-pediatric interaction information.
Suggested Improvement
Limit claims to the supplied label excerpts for PEPCID tablets: specify indications (DU, GU, symptomatic nonerosive GERD, erosive esophagitis by biopsy), provide label-supported dosing regimens and renal impairment adjustments, state the actual contraindication (serious hypersensitivity), and avoid unfounded assertions about Tums/magnesium-aluminum binding, timing separation, pregnancy safety, and non-label duration comparisons with other products.